Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 5/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | FLT4 | P35916 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pr-104 SCHEMBL31060232 | 1.00 | KMT2A (0.36) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL13338201 | 0.92 | TDP1 (0.38) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL3422264 | 0.92 | KMT2A (0.36) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL3418938 | 0.92 | KMT2A (0.36) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL3589344 | 0.91 | KMT2A (0.40) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL13338135 | 0.90 | KMT2A (0.38) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL366334 | 0.90 | KMT2A (0.38) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL29468020 | 0.90 | KMT2A (0.38) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL3420379 | 0.90 | MEN1 (0.33) | KMT2AMEN1HPGDNPSR1NPC1 | |
| SCHEMBL13338209 | 0.88 | KMT2A (0.36) | KMT2AMEN1HPGDNPSR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374566-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | LANKENAU INST FOR MEDICAL RESESARCH (US) | 2024-11-14 | — | — | US | claimed |
| EP-4176876-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | Lankenau Institute for Medical Research (US) | 2023-05-10 | — | — | EP | claimed |
| CN-115927619-A | System for leukemia diagnosis and treatment | 杭州赫玛生物科技有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-115927622-A | System for leukemia diagnosis and treatment | 杭州赫玛生物科技有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-115927621-A | System for leukemia diagnosis and treatment | 杭州赫玛生物科技有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-115927620-A | System for leukemia diagnosis and treatment | 杭州赫玛生物科技有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-108937848-B | System for leukemia diagnosis and treatment | 赫玛超生物科技(上海)有限公司 | 2022-12-09 | — | — | CN | claimed |
| EP-3681498-B1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | LANKENAU INST MEDICAL RES (US) | 2022-10-05 | — | — | EP | claimed |
| US-20220249522-A1 | Hypoxia Targeting Compositions and Combinations Thereof with a PARP Inhibitor and Methods of Use Thereof | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-08-11 | — | — | US | claimed |
| EP-2858974-B9 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORP (JP) | 2022-07-20 | — | — | EP | claimed |
| US-20100121091-A1 | Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-13 | — | — | US | claimed |
| US-20100010094-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-01-14 | — | — | US | claimed |
| US-7629332-B2 | Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-12-08 | — | — | US | claimed |
| WO-2008033039-A1 | CANCER TREATMENT | PATTERSON ADAM VORN (NZ) | 2008-03-20 | — | — | WO | claimed |
| US-20080064665-A1 | Combination approaches to cancer treatment | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-03-13 | — | — | US | claimed |
| US-20070032455-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNIVERVICES LIMITED (NZ) | 2007-02-08 | — | — | US | claimed |
| EP-4724077-A1 | COMBINATION OF BACTERIAL STRAINS TO INHIBIT PATHOGENS IN ANIMALS | Phibro Animal Health Corporation (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20260062578-A1 | IMAGE FORMING METHOD, IMAGE FORMING APPARATUS, IMAGE, AND INKJET INK | KONICA MINOLTA INC (JP) | 2026-03-05 | — | — | US | disclosed |
| US-20080064665-A1 | Combination approaches to cancer treatment | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-03-13 | — | — | US | disclosed |
| US-20070032455-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNIVERVICES LIMITED (NZ) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062578-A1 | IMAGE FORMING METHOD, IMAGE FORMING APPARATUS, IMAGE, AND INKJET INK | ACIN1, ILK, KRT18 | KMT2A 3140/4885MEN1 3175/4885HPGD 4101/4885 |
| US-20080064665-A1 | Combination approaches to cancer treatment | NPM1, NOX3, TYRO3 | KMT2A 2479/4885MEN1 2798/4885HPGD 1481/4885 |
| US-20100121091-A1 | Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom | HRH2, HRH4, H1-2 | KMT2A 75/4885MEN1 2521/4885HPGD 1510/4885 |
| US-20070032455-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | NAPRT, NTPCR, PNP | KMT2A 1372/4885MEN1 3896/4885HPGD 109/4885 |
| US-20100010094-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | NAPRT, NTPCR, QDPR | KMT2A 1079/4885MEN1 3811/4885HPGD 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.